DRAK2-IN-16

CAS No. 871837-60-4

DRAK2-IN-16( —— )

Catalog No. M16339 CAS No. 871837-60-4

DRAK2-IN-116 is a potent, selective DRAK2 inhibitor with IC50 of 3 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 194 Get Quote
50MG 896 Get Quote
100MG 1566 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    DRAK2-IN-16
  • Note
    Research use only, not for human use.
  • Brief Description
    DRAK2-IN-116 is a potent, selective DRAK2 inhibitor with IC50 of 3 nM.
  • Description
    DRAK2-IN-116 is a potent, selective DRAK2 inhibitor with IC50 of 3 nM, shows weak inhibition for DRAK1 (IC50=51 nM) and no significant activity against DAPK1/2/3 (IC50>1 uM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    DAPK
  • Recptor
    DAPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    871837-60-4
  • Formula Weight
    376.416
  • Molecular Formula
    C21H20N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (265.67 mM)
  • SMILES
    CCCCC(NC1=CC2=C(NC(/C2=C3NC4=C(C=CC=C4)C\3=N\O)=O)C=C1)=O
  • Chemical Name
    N-((2Z,3E)-3-(hydroxyimino)-2'-oxo-[2,3'-biindolinylidene]-5'-yl)pentanamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Jung ME, et al. Bioorg Med Chem Lett. 2016 Jun 1;26(11):2719-23.
molnova catalog
related products
  • DAPK-IN-2

    DAPK-IN-2 (WAY-380496) is a DAPK inhibitor. DAPK-IN-2 has potential anticancer activity, regulates autophagy and can be used to study cerebral infarction and ischemic diseases.

  • HS94

    HS94 (DAPK3 inhibitor HS94) is a selective DAPK3 inhibitor with Ki of 126 nM, >20-fold selectivity over Pim kinases.

  • DRAK2-IN-16

    DRAK2-IN-116 is a potent, selective DRAK2 inhibitor with IC50 of 3 nM.